Exchange: NYSEMkt·Updated 07:50 PM EDT
STXS logo

STXSStereotaxis Inc

$1.29
$0.12
(8.51%)
Today
Closed $1.29
$0.0099
(0.77%)
After Hours
EarningsAug 11
Mkt Cap$126.33M
Vol1.3M
News
all
press releases
Can ISRG Defend Its Leadership as Global Competition Intensifies?
ISRG is countering rising global robotic surgery competition with tiered platforms, AI features and a broad ecosystem focused on value over price.
Zacks
More News
ISRG to Report Q2 Results Next Week: Should You Buy the Stock Now?
ISRG is set to report Q2 results on July 16, with sales and EPS expected to rise, while investors weigh margin pressure against strong adoption of da Vinci 5.
Zacks
ISRG's Capital Placement Surge: Demand Strength or Upgrade Cycle Peak?
ISRG placed 431 da Vinci systems in Q1 2026, but rising trade-ins and leasing growth raise questions about whether demand is structural or upgrade-driven.
Zacks
ISRG's Ion Platform: A Major Growth Engine in Lung Cancer Care?
ISRG's Ion platform saw 39% procedure growth in Q1, with new clinical data strengthening its role in lung cancer diagnosis.
Zacks
Stereotaxis Inc. (STXS) Reports Q1 Loss, Lags Revenue Estimates
Stereotaxis (STXS) delivered earnings and revenue surprises of +25.00% and -30.87%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks
Inogen (INGN) Reports Q1 Loss, Beats Revenue Estimates
Inogen (INGN) delivered earnings and revenue surprises of -25.00% and +3.29%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks
Sight Sciences, Inc. (SGHT) Reports Q1 Loss, Beats Revenue Estimates
Sight Sciences (SGHT) delivered earnings and revenue surprises of +14.30% and +6.06%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks
Integra LifeSciences (IART) Beats Q1 Earnings and Revenue Estimates
Integra (IART) delivered earnings and revenue surprises of +32.78% and +2.74%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks
Stereotaxis Stock Up on First U.S. MAGiC Procedures Post Approval
STXS stock gains after first U.S. MAGiC procedures, marking a key milestone in robotic cardiac care and boosting its growth outlook.
Zacks
STXS to Acquire Robocath to Lead in Endovascular Robotics Market
Stereotaxis expands in robotic surgery with Robocath acquisition, aiming to build a comprehensive endovascular platform and unlock growth opportunities.
Zacks
<
1
2
...
>

Advertisement|Remove ads.